According to the reports, the clinical benefit of combining anti-LAG-3 (relatlimab) and anti-PD-1 (nivolumab) was observed for melanoma patients with progressive disease during prior nivolumab monotherapy, and the objective response rate (ORR) was 3 fold higher in patients with LAG-3 positive than in LAG-3 negative patients (45, 46). Here, PDCD1 is linked to melanoma.